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Optimising the survival of renal allografts is of crucial
importance, especially in developing countries where donor
organs are at a premium and alternative forms of treatment for
end-stage renal failure are often not readily available.  Patient
survival is one of the most important determinants of graft
survival and it has been estimated that 9 - 30% of patients die
with functioning grafts,1,2 making patient mortality one of the
most important causes of graft loss.2 Numerous factors are
known to influence the survival of recipients of renal allografts
as well as their transplanted organs.3 Much emphasis has been
placed on the impact of immunosuppressive agents 4 and HLA
compatibility5 on outcome, while there is a paucity of
information on those factors over which the patient and
physician have no control.  In this study we undertook to
investigate the impact of certain demographic factors, namely
age, race and gender, on the outcome of renal transplantation.    
Most reports detailing outcome of renal transplantation
originate from developed countries where there is generally
ready access to renal replacement treatment and other
resources.  In contrast, patients with irreversible renal failure in
developing countries have very limited, if any, access to any
form of renal replacement treatment, and renal transplantation
is often the only long-term option — provided that patients
have a suitable living donor.  In this setting there is a bias
towards treating younger patients, and males have greater
access to treatment than females.6
In common with other developing countries South Africa has
limited resources and only a fraction of patients with
irreversible renal failure receive treatment.  However, unlike
many other developing countries South Africa has had an
active cadaveric renal transplant programme for several
decades.  In one of the earliest reports of graft and patient
survival our sister hospital (Groote Schuur Hospital) reported
its experience with ciclosporin.7 Although the number of
patients treated was small and the follow-up short, the 1-year
patient and graft survival rates were impressive, being 88%
and 94%, respectively.   Our own renal transplant programme
was initiated in 1976 and is an important complement to our
chronic dialysis programme.
This study looked specifically at the influence of
demographic factors on both patient survival and the survival
of renal allografts since the inception of our programme.  Our
experience confirms the importance of age in the survival of
both patients and renal allografts and the lack of impact of race
on survival.   
Subjects and methods
The study population consisted of all patients receiving first
cadaveric renal transplants at Tygerberg Academic Hospital,
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Background. Optimising renal allograft survival is crucially
important in developing countries because of limited
resources to treat irreversible renal failure.  However,
although many factors can be manipulated to improve
outcome, certain demographic factors are immutable in
individual patients.  The present study evaluated the impact
of age, gender and race on the outcome of renal
transplantation.
Methods. Relevant data were reviewed for 542 patients
receiving primary renal allografts over a 23-year period. The
survival of patients and grafts were calculated using the
Kaplan-Meier method.  Both univariate and multivariate
analyses were used to determine the association between the
demographic factors and patient and graft survival. 
Results. Actuarial survival of both patients and grafts
decreased with increasing age. The most striking differences
were demonstrated when patients older than 40 years were
compared with younger patients. However, when patient
survival was censored for death with functioning grafts — a
very important cause of graft loss — then actuarial graft
survival improved with increasing age.  There was no gender
difference in graft survival, but female recipients of renal
allografts had a higher mortality than their male counterparts.
There were no racial differences in either patient or graft
survival.  
Conclusions. Age is an important determinant of outcome
after renal transplantation, but race is not.   Gender does not
influence graft survival, but females do have a higher overall
mortality rate following renal transplantation at our centre. 
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which is attached to the University of Stellenbosch, for the
period April 1976 to March 1999.  Over the 23-year period 542
patients received 623 renal allografts: 64 patients received a
second graft, 7 received a third, and 1 patient a fourth.  The
demographic details of the patients are shown in Table I.
Geographically the hospital serves approximately 50% of the
Western Cape, which has a population of almost 4 million
inhabitants (census 1996).  The population served is racially
heterogeneous, with the mixed race group (coloured) forming
56% of the population and whites 21%.  The number of blacks
in the Western Cape is relatively small (22%) compared with
other South African provinces because of the enforced racial
segregation policy of the previous South African government
that confined certain race groups to particular areas.  
All patients with end-stage chronic renal failure at our
institution are assessed by a committee comprising the
attending physician, social worker, nephrologists and other
renal unit staff.  Patients are accepted for transplantation with a
living related donor (of which there are relatively few) or to the
waiting list for cadaveric transplantation, with the same
criteria.  Cadaveric organs are allocated based mainly on time
on the waiting list within each blood group.  The average
waiting time is 12 months for cadaveric transplantation.  At our
hospital, as in most public hospitals offering renal replacement
treatment in South Africa, patients not suitable for renal
transplantation for any medical reason such as severe cardiac
disease, psychiatric disease or malignant disease are not
offered dialysis or transplantation.  In addition, social factors
are taken into consideration and patients who live in rural
areas where there are no haemodialysis facilities and who do
not have access to running water are also denied treatment.
Patients over the age of 60 years are also generally treated
conservatively.
No discrimination is made on the basis of gender.
Immunological factors (panel-reactive antibodies, re-
transplants) do not jeopardise access to the programme but are
taken into consideration when allocating cadaveric organs.
Despite this, there is no significant gender difference in the
number of patients receiving organs compared with the general
population and the dialysis population. In our institution the
mean waiting period for females on dialysis before receiving an
organ for transplantation is, however, (statistically)
significantly longer than that of males (14 months compared
with 10 months).
Patients with diabetic nephropathy are subjected to
additional very stringent investigation before acceptance.  At
this time diabetic nephropathy is not the major problem in
South Africa that it is in industrialised countries8 and in our
renal transplant population it accounted for less than 4% of
renal allograft recipients, reflecting the strict selection criteria
used for these patients.  
The standard immunosuppressive regimen used until
October 1983 was azathioprine at 1 - 2 mg/kg per day and
methylprednisolone at doses varying between 1 mg/kg and 2
mg/kg per day over the years.  A total of 123 patients received
conventional treatment over the 7-year period.  From October
1983, ciclosporin was included as part of triple therapy and
was administered to 419 patients.  Patients were maintained on
ciclosporin for the life of the graft.  The dose of ciclosporin was
regularly monitored and the dose adjusted to maintain whole
blood trough levels between 250 and 350 ng/l.  The dose of
ciclosporin was reduced at 3 - 6 months and whole blood
trough levels were maintained between 150 and 250 ng/l.
Cytochrome P450 inhibitors such as ketoconazole and
diltiazem were not used routinely to allow reduction in the
dose of ciclosporin.  Under the triple immunosuppressive
regimen oral methylprednisolone was reduced at 3 - 6 months
to a maintenance dose of 8 mg per day. Azathioprine was
administered at doses of 50 - 100 mg per day, with the majority
of patients receiving the lower dose.  Acute rejection was
treated with intravenous ‘pulses’ of methylprednisolone 
250 - 500 mg per day for 3 consecutive days.  Polyvalent anti-
thymocyte globulin or antilymphocyte globulin as well as
OKT3 monoclonal antibodies were used individually (and
occasionally sequentially) to treat steroid-resistant rejection as
part of rescue therapy.
Table I.  Demographic characteristics of renal allograft recipients,









< 20 36 (6.6)
20 - 29 126 (23.2)
30 - 39 151 (27.9)
40 - 49 160 (29.5)




Primary renal disease White C o l o u red & black
(N = 185) (N = 357)
Chronic glomerulonephritis 58 (31) 161 (48)
Hypertension 10 (5) 91 (27)
Cystic kidney disease 35 (19) 16 (5)
Analgesic nephropathy 7 (4) 3 (1) 
Diabetes mellitus 13 (7) 8 (2)
Hereditary kidney disease 5 (3) 0
Systemic lupus erythematosus 5 (3) 5 (1)
Miscellaneous 5 (3) 12 (3)
Unknown 9 (5) 12 (3)
ORIGINAL ARTICLES
Initially, antimicrobial prophylaxis was only used in patients
with a history or radiological evidence of tuberculosis.  Since
1996 isoniazid prophylaxis (300 - 400 mg/day) has been used
routinely in the first year after transplantation.
Cytomegalovirus (CMV) infections started becoming a problem
in out unit approximately 10 years ago and still remain a
uncommon cause of mortality in our patients.   Since 1999
aciclovir has been used for the first 6 - 12 months in all renal
transplant patients who are serologically CMV-positive or
where the organ donor is positive.   Pneumocystis carinii
pneumonia (PCP) has occurred in 20 patients after
transplantation, all within the last decade.  It has therefore
become routine practice in our unit to use prophylactic co-
trimoxazole (1 tablet daily) in the first year.   Records of all the
patients transplanted since the inception of our programme
have been entered into a computer-based database.   All
patient-related data are entered into the database as well as the
point of failure of the graft.  The database was locked in March
1999 to allow follow-up of at least 2 years after transplantation.
The mean follow-up period was 6.3 years. 
Statistical methods
Values are expressed as means with 95% confidence intervals
(CIs).  The means of normally distributed data were compared
using the Student’s t-test.  The chi-square (X2) test was used to
examine categorical data.  Cumulative survival of patients and
grafts was calculated using Kaplan-Meier plots, and
significance of difference between groups using either the log-
rank test or the X 2-test.  Multivariate regression analysis of
demographic factors prognostic of patient and graft survival
was performed with proportional hazards analysis, using
stepwise elimination to select variables for the model.  For the
purposes of this study, allograft failure was defined by the
institution of long-term dialysis after transplantation or patient
death.    
Results (Table II)
The mean age of renal allograft recipients at the time of first
kidney transplant was 37.0 years (CI: 36.0 - 37.9), with no
significant gender or racial differences. Patient survival
deteriorated progressively with advancing age (Fig. 1).
However, patients over the age of 40 years seemed to have
very similar outcomes.  The survival of patients over 40 was
significantly greater than that of younger patients.  More
importantly, the discrepancy in survival between the older and
younger group increased with time (Fig. 2).  The commonest
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Table II. Estimated relative risks for the Cox proportional hazard model considering demographic factors that influence patient and graft
survival after renal transplantation
Patient survival Graft survival
RR 95% CI p-value RR 95% CI p-value
Age (yrs)
< 20 0.88 0.50 - 1.54 0.645 1.12 0.70-1.78 0.646
20 - 29 1.00 1.00
30 - 39 yrs 1.94 1.38 - 2.74 0.0001 1.30 0.97 - 1.74 0.083
40 - 49 2.92 2.09 - 4.07 < 0.0001 1.50 1.12 -1.99 0.006
‡ 50 2.95 1.96 - 4.45 < 0.0001 1.59 1.11 -2.28 0.012
Gender
Male 1.00 1.00
Female 1.39 1.11 - 1.74 0.005 1.16 0.94 -1.37 0.154
Race
White 1.00 1.00
Coloured 1.28 1.01 - 1.64 0.043 1.10 0.88 - 1.37 0.394
Black 1.29 0.87 - 1.91 0.205 1.01 0.70 -1.44 0.974
RR = relative risk; CI = confidential interval.
Fig. 1.  Influence of recipient age on the survival of patients
following renal transplantation  (p = 0.0000, c2 = 35.2, degrees of
freedom (df) = 4).
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cause of death was infection, which accounted for 43% of
deaths (Table III).   The main cause of mortality was infection,
both under conventional therapy and triple therapy.  However,
there was no significant difference in infective mortality under
the two forms of treatment.   Septicaemia and pulmonary
infections together accounted for almost 70% of all infections.
In the patients under ciclosporin, infections competed with
cardiovascular disease as the main cause of patient mortality.
Of the 542 patients transplanted, 321 (59%) had died by 31
March 1999.  Of these, 180 (56%) died with functioning grafts.
Expressed differently, at closure of the database 380 grafts had
failed, with patient death accounting for 180 (47.3%) of all
grafts lost.  The remaining patients lost renal function
progressively over months to years due to chronic allograft
nephropathy.
Renal allograft survival also deteriorated with advancing age
(Fig. 3) and mirrored the patient survival curves.  The
exception was the group of patients aged under 20 years who
fared as poorly as those over 50 years initially, but whose renal
allograft survival improved later.  The pattern of the renal
allograft survival curves suggested that death of patients with
functioning grafts was an important determinant of graft
survival.   Indeed, over the 23-year period of this study, death
with functioning grafts occurred in 44% of patients aged over
40 years and 26% of those younger than 40 years.  When the
impact of death was censored for, renal allograft survival
curves were dramatically different (Fig. 4). The older patients
then had better graft survival than the younger patients,
although the difference failed to reach statistical significance.
Graft loss was due to death in 31% of women and 35% of men;
the difference was not significant.  
There was no significant difference in either patient (not
shown) or graft survival (Fig. 5) in the different race groups by
univariate analysis, although using Cox’s regression patient
survival was significantly better in coloured than white
patients.  Patient and graft survival by race group remained
virtually parallel throughout the study period.  Survival of
both patients (Fig. 6) and grafts (not shown) were better in
males than females.  However, only patient survival achieved
statistical significance (Table II).
Fig. 2.  Survival of renal allograft recipients aged 40 years and less
compared with those aged more than 40 years at the time of
transplantation (p = 0.0000, log-rank test).
Table III. Causes of patient mortality after kidney transplantation
(N = 180)*
Parameter N %
Cardiovascular disease 65 36.1
Infections 72 40.0
Septicaemia 33 46†





* The cause of mortality was not available for 116 patients (39.2%).
† Percentage of infections.
‡ All but 4 infections were bacterial: 3 patients had fungal infections and 1 had a viral
infection; included are 4 patients with Pneumocystis carinii pneumonia (PCP). 
Fig. 3.  Renal allograft survival in patients in different age 
percentiles (p = 0.15, c 2 = 6.7, df = 4).
Fig. 4.  Renal allograft survival in patients censored for death with




In a developing country setting where resources are limited it
is crucial that renal allograft survival be optimised.  However,
it is important to appreciate that there are certain factors over
which neither the patient nor the physician has any control.
Our data demonstrate the superiority of patient and graft
survival in younger patients.  Our data also suggest that the
loss of grafts in older patients is closely related to patient
mortality.  Death accounted for one in three of all grafts lost in
our study.  In a recent larger survey Ojo et al.1 reported that
38% of more than 18 000 deaths were deaths with graft
function and that this accounted for 43% of graft loss.
Interestingly, infections (mostly of the lungs and septicaemia)
were the commonest cause of death in our cohort even after the
first year.  In very young patients who experience greater graft
loss early on, discrepancies in kidney size leading to vascular
problems may account for the early loss of grafts; the higher
propensity for acute rejection is perhaps the other explanation
for the high early graft loss.  The explanation for these causes
of graft loss is strongly supported by our observation that
when graft loss is censored for loss due to patient death, the
graft survival improves with age.  This observation confirms
the findings of others.9 The most likely explanation for this is
declining immunological function, which results in improved
graft survival.10 However, this same mechanism may account
for the increased susceptibility to infection in older patients
that leads to early death.  With these observations in mind it
seems appropriate to suggest that immunosuppression should
be reduced in older patients.  Several factors have been
identified as being predictors of reduced graft survival in the
elderly patient, including increasing patient age, a pre-
transplant history of non-skin cancer, time on the waiting list of
less than 1 year, and tobacco use.9
Much more controversial is the impact of gender on patient
and graft survival following renal transplantation.  Our own
finding of a higher mortality in female patients is corroborated
by evidence presented by Troppmann et al.11 who found that
females had a 25% greater risk of dying than males but that the
difference was not significant.  An earlier report by Gorlén et
al.,12 who followed up patients for a mean period of 9.5 years,
also found a non-significant increase in mortality in female
patients (60% compared with 39%).  These findings contrast
with those of Arend et al.13 who report a lower mortality among
women, both in the first year post-transplant as well as during
long-term follow-up.  Woo et al.,14 reporting on ciclosporin-
treated patients, found that women had a lower mortality than
men (hazard ratio: 0.66).  In a more recent study,1 male patients
had a 16% higher risk of dying with graft function relative to
females. The higher mortality observed in our cohort remains
difficult to explain.  One possibility is that since a standard
immunosuppressive regimen was used throughout, female
patients received relatively more immunosuppression for their
body mass and were therefore more prone to the complications
of over-immunosuppression.     
Even more controversial are ethnic differences in the
outcome of renal transplantation.  In the present study, in
contrast to reports both from South Africa15 and elsewhere,16
coloured and black patients taken together, and specifically
black patients, had the same graft survival as white patients.
The long-term survival of renal allografts in black patients has
been reported to lag behind that of all other race groups.17 In
the latter study the 
1-year and projected 10-year survival of first cadaver donor
transplants were 84% and 47%, respectively, in white recipients
compared with 81% and 23% in a similar-sized cohort of black
recipients in the same age range.  After the first year the rate of
graft loss was more than double that of white recipients (half-
life of 10.8 years versus 4.9 years).  Earlier studies indicated
that racial differences appeared shortly after transplantation,
with more early rejection and 8 - 10% more graft loss in blacks
at 1 year.  The half-life of grafts in blacks was 30 - 40% that of
whites.18 Although this situation has improved and rates of
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Fig. 5.  Renal allograft survival in recipients of different race groups.
There was statistically no difference in survival rates (p = 0.74, c 2 =
0.60, df = 2).
Fig. 6.  Patient survival on the basis of gender (p = 0.025, log rank
test).
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early rejection and graft loss now approximate those of whites,
this has not resulted in improved long-term success as blacks
remain at risk of late graft loss.17,18 Important determinants of
outcome may be histocompatibility differences,16 possibly
poorer blood pressure control and socioeconomic factors.  As
regards immunological issues, Asian patients who have similar
difficulties finding histocompatible donors experience superior
graft survival rates to those of white patients.19 A higher
incidence of late graft rejection among black recipients may be
an indication of greater difficulty in maintaining adequate
immunosuppression for these patients.20 Most studies of
outcome of renal transplantation in black patients are based on
the African-American population.  The reason that South
African black patients respond differently to their American
counterparts is uncertain.  Hypertension, which is a key factor
in the aetiology of end-stage renal failure in African Americans,
is also a key predisposing cause in our population.21 This
continues to be a problem in our patients even after
transplantation.  Although several studies have sought an
association between poorly controlled blood pressure and the
survival of allografts,22,23 none have established a cause-and-
effect relationship.  Young and Gaston21 have suggested that
poor socioeconomic status is a predictor of poorer outcome.
Black patients suffer the worst socioeconomic deprivations of
all race groups in our country, are the least educated and have
the least access to medical care.  Our observation of equal
outcome among white patients and coloured and black patients
challenges the validity of arguments that the racial
discrepancies are related to issues such as socioeconomic
factors, educational level and compliance with treatment.
Although not part of this study, our small pool of transplant
recipients makes it very difficult to obtain good HLAmatching
on any of the patients.  Very few blacks are donors, with most
organs being obtained from whites and coloureds in our
province.   Despite this the outcome of renal transplantation
was comparable.  One important difference between our
situation and that in North America is that we pre-select
transplant patients as indicated above. Patients with a history
of poor compliance, very poor socioeconomic conditions that
preclude regular commuting to a dialysis centre, or social
conditions that do not allow the institution of continuous
ambulatory peritoneal dialysis are not accepted for renal
replacement treatment.  However, even after this selection
process, South African black patients are much worse off
socioeconomically than their white counterparts.24
Much less is known about the survival of black patients after
renal transplantation.  Our own experience reported here failed
to show a racial discrepancy in outcome, either early after
transplantation or after prolonged follow-up.  This supports
the findings of the US Renal Data System 1999 Annual Report8
which showed that patient survival after renal transplantation
was virtually identical in black and white patients; the survival
rate at 1 year was 96.5% and 95.7%, respectively, in recipients
of cadaveric donor allografts and even better in recipients of
kidneys from living donors.   Another recent study 1 found that
African American and other minority race groups had a lower
risk of death, after controlling for other factors, than their white
counterparts.  
Comparisons with other developing countries are more
problematic.  In contrast to the developed countries, where
most transplants are from cadaveric donors, most developing
countries,6 perhaps with the exception of the Latin American
countries,25 perform related or unrelated living-donor renal
transplants, which often form the basis of their renal
replacement programmes.  In the few developing countries that
do perform cadaveric transplants, the 1-year survival rates of
patients range from 75% to 91% and 1-year graft survival rates
range from 66% to 79%. 6 Recently, Opelz25 reviewed the renal
allograft survival experience in Latin America and found
cadaveric donor transplant recipients to have a 1-year survival
of 74%, while patient survival was over 80%.  There was a
relatively modest influence of age on graft survival but patient
survival decreased strikingly with advancing age. Unlike the
current study, graft survival censored for patient survival was
not studied.     
In sum, our report is one of the first from a developing
country to look at the impact of certain demographic factors on
the outcome of patients and grafts following renal
transplantation.  We have shown that race does not appear to
be an important factor in determining the survival of either
renal transplant patients or their grafts.  Age, on the other
hand, is an important determinant of renal allograft outcome
but has an even more striking influence on patient survival.   If
graft survival is censored for patient death then graft survival
is better in older patients.  Gender differences in patient and
graft survival are less impressive.   
Dr Jane Gralla is thanked for her valuable assistance with certain
aspects of statistical analysis.
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Lung cancer is the leading cause of cancer mortality in most
countries, with the global incidence increasing by 0.5% per
year.1 The adrenal glands are common sites of metastases, as
evidenced by a series of 500 consecutive cancer necropsies,
where 42% of metastatic lung cancers involved the adrenal
glands.  This high prevalence of adrenal metastases may reflect
the rich sinusoidal blood supply and high local concentration
of glucocorticoids, which may promote implantation of
metastases.2
Overt hypoadrenalism is uncommon in patients with stage 3
and 4 bronchogenic carcinoma
Ian L Ross, Suzaan Marais, Peter Raubenheimer, Raymond Abratt, Sedick Isaacs, Steven Soule
Introduction. Lung cancer is the leading cause of cancer
mortality in most countries. The adrenal glands are common
sites of metastatic lung cancer as approximately 40% of
subjects with stage 4 bronchogenic carcinoma have adrenal
metastases. The prevalence of biochemical hypoadrenalism is,
however, remarkably poorly documented. 
Objectives. Our study aimed to determine the prevalence of
primary hypoadrenalism, as defined by a subnormal cortisol
response to the 250 µg adrenocorticotrophic hormone (ACTH)
stimulation test, in patients with stage 3 and 4 lung cancer.
Methods. Thirty patients with stage 3 and 4 bronchogenic
carcinoma were prospectively recruited from the bronchus
clinic. Demographic data and electrolytes were recorded and
each patient had a 250 µg ACTH stimulation test to determine
the prevalence of overt adrenal insufficiency, defined as a +30
minute cortisol of less than 550 nmol/l.
Results. The median age and quartile deviation was 62 (10)
years and the median basal cortisol was 429.5 (321) nmol/l.
The median peak cortisol was 828.5 (342) nmol/l (range 
536 - 1 675 nmol/l). Twenty-eight patients (93.3%) had an
appropriate rise of cortisol to greater than 550 nmol/l
following 250 µg ACTH stimulation. Two patients (6.7%) had
mild primary adrenal failure with a peak cortisol between 500
and 550 nmol/l associated with a raised plasma ACTH
concentration (131.4 and 10.5 pmol/l, normal 2.2 - 10 pmol/l).
Twenty-eight patients (92.9%) were normonatraemic, while
the two hyponatraemic patients had biochemical evidence of
the syndrome of inappropriate antidiuretic hormone
secretion. 
Conclusion. In conclusion, despite evidence that the adrenal
glands of patients with disseminated bronchogenic carcinoma
are frequently affected by metastatic disease, biochemical
evidence of clinically significant hypoadrenalism is relatively
uncommon and is not accurately predicted by electrolyte
abnormalities. 
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